Cite
639PVolume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery?
MLA
Nagasawa, S., et al. “639PVolume Reduction Rate of the Primary Tumor of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy: Could This Measurement Be a Surrogate End Point for Survival before Surgery?” Annals of Oncology, vol. 29, Oct. 2018, p. N.PAG. EBSCOhost, https://doi.org/10.1093/annonc/mdy282.023.
APA
Nagasawa, S., Ogata, T., Hara, K., Shimoda, Y., Nakazono, M., Kumazu, Y., Hayashi, T., Yamada, T., Rino, Y., & Masuda, M. (2018). 639PVolume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery? Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy282.023
Chicago
Nagasawa, S, T Ogata, K Hara, Y Shimoda, M Nakazono, Y Kumazu, T Hayashi, T Yamada, Y Rino, and M Masuda. 2018. “639PVolume Reduction Rate of the Primary Tumor of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy: Could This Measurement Be a Surrogate End Point for Survival before Surgery?” Annals of Oncology 29 (October): N.PAG. doi:10.1093/annonc/mdy282.023.